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Available online 7 April 2018Systemic lupus erythematosus (SLE) is an autoimmune connective tissue disorder that can involve any organ sys-
tem. Central nervous system involvement can be a severe life threatening complication, ultimately resulting in
severe neurodegenerative changes. Magnetic resonance imaging suggests that neurodegeneration, which may
have deleterious effects on brain function, may occur early in SLE and experimental models suggest that neuro-
protection may be feasible and beneﬁcial.
The retina is an extension of the brain. Recent ophthalmic imaging technologies are capable of identifying early
changes in retinal and choroidal morphology and circulation that may reﬂect CNS degeneration. However, their
utility inmonitoring CNS involvement in SLE has been poorly studied as these have only been performed in small
cohorts, in a cross-sectional design, non-quantitatively and without correlation to disease activity.
The authors aim to review the current understanding of neurodegeneration associated with SLE, with particular
focus on the visual pathway. We describe the neuropathology of the visual system in SLE and the evidence for
retinal and choroidal neurodegenerative and microvascular changes using optical coherence tomography tech-
nology.We aim to describe the potential role of optical imagingmodalities inNPSLE diagnosis and their likely im-
pact on the study of neuronal function.
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6221. Introduction
1.1. Systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a systemic, autoimmune dis-
order that can involvemultiple organ systems. It has a global prevalence
of 20–150 cases per 100,000 people [1,2], preferentially affecting
women of childbearing age (female-to-male ratio is close to 9:1). Over
the last four decades, there has been an increase in incidence as well
as survival, reﬂecting the better diagnostic acuity, a better understand-
ing of the pathogenesis of the disease and advances in the therapeutic
approach [3]. The main cause of death is also changing. While in the
past decade most patients died from infection and complications of ac-
tive SLE, nowadays thrombotic events are becoming themost important
cause of mortality [4–6].1.2. Neuropsychiatric SLE (NPSLE) – clinical features
Central nervous system (CNS) involvement has been reported to
occur in 12% to 95% of SLE patients [7]. Thiswide range in prevalence re-
sults from themultitude ofmanifestations recognized as neuropsychiat-
ric (NP) systemic lupus erythematosus. In 1999, theAmerican College of
Rheumatology has deﬁned 19 NPSLE syndromes [8], including 12 CNS
and 7 peripheral nervous system manifestations (Table 1). Acquisition
of valuable treatment strategies poses the need for early recognition of
nervous system involvement in SLE and responses to the medication.
However, there is also the issue of attribution of NP events to SLE as
these conditions may arise from multiple causes, making it difﬁcult to
distinguish between NPSLE and other neurologic conditions [9]. More
recently, in addition, SLE has been associated to an increased risk of de-
mentia [10].
NPSLE remains a diagnostic challenge as there are no widely ac-
cepted biomarkers for patients who have subclinical involvement.
Moreover, for patients with neuropsychiatric events, their lack of spec-
iﬁcity for SLEmakes attribution difﬁcult despite advances in neuroimag-
ing and other diagnostic strategies. It has been demonstrated that SLE
patients have higher rates of post-steroid NP symptoms which might
have erroneously been diagnosed as NPSLE, accounting for the wide
range in prevalence [11]. Magnetic resonance imaging (MRI) is the im-
agingmethod of choice, where atrophy involvingmainly the frontal andTable 1
Neuropsychiatric syndromes in systemic lupus erythematosus as deﬁned using the
American College of Rheumatology nomenclature [8].
Central nervous system Peripheral nervous system
Aseptic meningitis Guillain Barré syndrome
Cerebrovascular disease Autonomic neuropathy
Demyelinating syndrome Mononeuropathy
Headache Myastenia gravis







Psychosistemporal grey matter and white matter is the hallmark of NPSLE [12].
Additionally, different NP syndromes and immunological patterns
have been associated to speciﬁc imagiologic ﬁndings [13,14]. However,
up to 50% of NPSLE patients have a normal exam [15]. On the other
hand, non-NPSLE patients also have high rates of abnormal brain
scans, indicating that MRI is not sufﬁcient to diagnose CNS involvement
[16]. Studies with functional MRI revealed an altered pattern of cortical
activation in sensorimotor areas, aswell as in some regions of the frontal
and parietal lobes and in the visual pathway [17]. A study with
18ﬂuorodeoxyglucose (18FDG) PET imaging to measure blood ﬂow and
glucose uptake in the brains of newly diagnosed SLE patients without
neurologic symptoms revealed increased 18FDG uptake (hypermetabo-
lism) in the white matter, which correlated with higher scores of dis-
ease activity index [18]. Taken together, these ﬁndings suggest that
overall lupus inﬂammatory activity is associated with inﬂammation in
thewhitematter of patients with SLE, irrespective of NPmanifestations.1.3. Neuropsychiatric SLE (NPSLE) – pathophysiology
NPSLE is a complex and incompletely understoodmedical condition.
Its pathophysiology is multifactorial and involves auto-antibody medi-
ated neuronal cell damage, immune complex depositions, inﬂammatory
and/or thrombotic microangiopathy, damage to the blood-brain barrier
and intrathecal production of proinﬂammatory cytokines [19,20]. An in-
ﬂammatory state may begin early in the course of the disease, accom-
pany disease relapses and eventually result in neuronal death [18].
More speciﬁcally, increased susceptibility to NPSLE has been de-
scribed in patients with apolipoprotein E polymorphism [21] which is
itself associated to an increased risk of Alzheimer's disease [22]. More
recently, an increased risk of NPSLE has been described to occur in pa-
tients with TREX 1 gene variants, involved in the regulation of apoptosis
and oxidative stress [23]. Anti-phospholipid antibodies are the autoan-
tibodies with the highest potential to cause brain damage in LES pa-
tients. A signiﬁcantly greater proportion of NPSLE patients have
positive titers as compared to non-NPSLE [24]. The exact pathogenic
mechanism of these antibodies is unknown but increasing evidence
supports the idea that, besides having a direct prothrombotic effect,
anti-phospholipid antibodies increase the expression of cell-adhesion
molecules and proinﬂammatory cytokines in the endothelium, thereby
increasing local inﬂammatory response [25,26]. Some studies also sug-
gest that anti-phospholipid antibodies directly bind to the neural tissue,
deregulating their functions and having an immediate pathogenic effect
[27]. Anti-neuronal antibodies with direct cytotoxic effects also have an
important role in the physiopathology of NPSLE [24]. Anti-ribosomal P
were related to hippocampal atrophy and memory impairment in
these patients [28] [29]. Elevated anti-ribossomal P, both in serum and
cerebrospinal ﬂuid, was also reported to have a strong association
with lupus related psychosis [30,31]. Antibodies against NMDA recep-
tor, which is responsible for activity-dependent synaptic plasticity and
long-term potentiation that underlie memory and learning [32,33], are
signiﬁcantly augmented in the serum of NPSLE patients [34]. The pres-
ence of anti-microtubule-associated protein 2 antibodies also correlated
with neuropsychiatric manifestations in SLE, namely psychosis, sei-
zures, neuropathy, and cerebritis [35].Increased cerebrospinal ﬂuid
levels of several cytokines, namely interleukin-6, interleukin-8 [36], in-
terleukin-1ß, interleukin-10 and tumor necrosis factor α (TNFα) were
demonstrated in several studies [37]. These proinﬂammatory cytokines
promote the synthesis of proteolytic enzymes, metalloproteinases,
619A. Dias-Santos et al. / Autoimmunity Reviews 17 (2018) 617–624which in turn induce damage to the brain parenchyma. Intrathecal
levels of matrix metalloproteinase-9 are elevated in SLE with CNS in-
volvement and its levels correlate with those of interleukin 6 and 8
[25]. Corroborating this data, a signiﬁcant increase in soluble bio-
markers of neuronal and astrocytic cell death, such as neuroﬁlament,
Tau and astroglial ﬁbrillary acidic protein in the cerebrospinal ﬂuid of
NPSLE patients has been demonstrated [38]. Recent research revealed
the importance of type I interferon ɑ signalling as cytokine abrogation
was sufﬁcient to prevent synapse loss and some behavioural pheno-
types in lupus-prone mice [39]. In addition, mitochondrial dysfunction
and disruption of neuron-glia metabolic coupling occurring as a result
of the increased oxidative stress are observed in the brain of patients
with systemic inﬂammation. This leads to decreased expression of
genes associated with synaptic plasticity and increased expression of
stress-response genes [40,41]. Additionally, reactive oxygen species, to-
gether with activated immune cells and proinﬂammatory cytokins, like
TNF-α and interleukin-1ß, can directly induce neuronal apoptosis
[7,42]. Taken together these ﬁndings indicate that systemic inﬂamma-
tion leads to an energy crisis of the brain that reduces its synaptic activ-
ity, thus resembling the hallmarks of the aged brain [7].
1.4. Central nervous system degeneration in SLE
The deﬁnition of neurodegeneration is neither simple nor consen-
sual, although universally accepted. In the strict sense of the word, neu-
rodegeneration corresponds to any pathological condition in which
there is primary loss of structure and/or function of neurons. In practice,
neurodegenerative diseases represent a large group of neurological dis-
orders with heterogeneous clinical and pathological expressions affect-
ing speciﬁc subsets of neurons in speciﬁc functional anatomic systems.
Furthermore, they are characterized by having a chronic relentless
course and an essentially unknown cause. Even when its cause is
known, for example in the case of Huntington's disease (defective
huntingtin caused by a mutation in HTT gene), the mechanism by
which it initiates the disease remains speculative [43]. Currently the
number of neurodegenerative syndromes reaches a few hundred, the
vast majority of which exhibits diffuse or focal loss of neurons with re-
active gliosis [43]. At least four main types of distinct neuronal death
have been deﬁned: apoptotic, necrotic, autophagic, and cytoplasmic
[44]. A common misconcept is the belief that only necrosis elicits in-
ﬂammation. The higher grade of inﬂammatory reaction in regions of ne-
crosis may simply reﬂect the higher number of dead cells. In the brain
microenvironment, especially in the context of neurodegeneration, the
inﬂammatory response is mainly local, even for necrosis. In other
words, the main cellular effectors are resident microglia and astrocytes,
instead of blood-borne neutrophils and monocytes [45].
The immune and nervous systems have coevolved from early inver-
tebrates to higher mammals, creating intricate cross-talk mechanisms.
This is not surprising since glial cells constitute no less than half the
cells in a mammalian brain [7]. Data from animal studies suggest that
both acute high bursts of systemic inﬂammation [46] or transient low
dose bouts can induce permanent brain dysfunction [47]. On the other
hand, intracerebroventricular minocycline injection, a tetracycline de-
rivativewhich reduces blood-brain barrier permeability and inhibits ac-
tivation and proliferation ofmicroglia, protects septicmice against long-
term memory impairment [48]. Animal studies also demonstrate that
systemic inﬂammation induces brain NADPH oxidative activity and ni-
tric oxide synthase (iNOS), with a signiﬁcant increase in oxidative
stress. Moreover, experimental administration of the anti-oxidants N-
acetylcysteine and deferoxamine shortly after murine sepsis resulted
in long-term neuroprotective effects [49].
2. The eye in SLE
SLE may affect almost any ocular structure, namely the eyelid, con-
junctiva, episclera, sclera, cornea, retina, retinal vasculature, uvealtract, optic nerve and orbit (1). Up to one-third of patients present ocu-
lar manifestations, which may precede extra-ocular systemic disease
[50]. Among these, posterior segment involvement may correlate with
SLE activity and/or CNS lupus (Table 2) [50].
Next we shall describe in, more detail, manifestations in speciﬁc oc-
ular compartments that may be associated to clinical or subclinical neu-
ronal involvement.
2.1. The optic nerve
Neuro-ophthalmic manifestations are rare, optic neuropathy being
the most common complication [52]. It most frequently manifests as
optic neuritis, with a moderate to poor visual prognosis [51] and a
favourable response to prompt steroid therapy [57,58]. Neuromyelitis
optica in patients testing positive for aquaporin-4 autoantibody has
also been described in SLE patients [59]. In this case the prognosis for
functional recovery is worse, even with high-dose corticotherapy or
plasmapheresis. Ischemic optic neuropathy [60,61] or chiasmopathy
[57] may also occur.
2.2. The choroid
Histopathology studies of the choroid have shown inﬂammatory cell
inﬁltrates within the choroid, as well as immunoglobulin and comple-
ment deposition in the choroidal vasculature and damage to the retinal
pigment epithelium [62]. There is a wide spectrum of manifestations.
Lupus choroidopathy can occur isolated or associated with retinopathy.
Subtle and subclinical changes in choroidal circulation have also been
demonstrated with indocyanine angiography in SLE patients with ne-
phropathy and no other signs of ophthalmic involvement [54]. On the
other hand it can present with serous retinal detachment, retinal pig-
ment epithelium detachment, retinal pigment epitheliopathy, choroidal
ischemia or effusion [50]. Lupus choroidopathy is usually a marker of
high disease activity, often correlated with CNS and renal disease [63].
2.3. The retina
Retinal involvement depends on the systemic control of disease ac-
tivity [64] and is strongly correlated to CNS involvement [55]. Damage
to the retina can be induced directly as a result of three main mecha-
nisms:microangiopathy, retinal vasculitis and/or severe vaso-occlusion.
Microangiopathy results from immune complexes deposition in vessel
walls and microemboli, which translates in intraretinal haemorrhages,
hard exudates, microaneurysms and cotton wool spots. Histopathology
reveals immunoglobulin and complement deposits, perivascular
monocellular inﬁltrate and rarely ﬁbrinoid necrosis [63,65]. Retinal vas-
culitis, affecting both veins and arterioles, is a much rarer presentation
with a signiﬁcantly worse prognosis than microangiopathy. The ﬁnding
of retinal vasculitis correlates with anti-phospholipid syndrome as well
as with the presence of CNS vasculitis [56,66]. Histopathologic speci-
mens show ﬁbrinoid change with thrombus formation without a true
arteritis [67]. Severe vaso-occlusion has a spectrum of clinical presenta-
tions ranging from occlusion of major retinal veins or arteries to
microembolisation of multiple small vessels presenting as Purtscher-
like retinopathy [50]. Indirect retinal damage can also occur secondary
to systemic hypertension from renal involvement or prolonged cortico-
steroid therapy.
Besides the above-mentioned clinical ﬁndings, retinal involvement
may be slowly progressive and subclinical. The retina is a neuronal tis-
sue with the same embryologic origin as the brain. It also contains neu-
rons – the ganglion cells – and unmyelinated axons – the retinal nerve
ﬁber layer (RNFL) – making it an ideal tissue to study CNS alterations.
In fact, early retinal changes that occur in neurodegenerative diseases
such asmultiple sclerosis [68], Alzheimer's disease [69] and Parkinson's
disease [70] can be tracked with optical coherence tomography (OCT).
These changes consist of macular thinning, mainly involving retinal
Table 2
Posterior segment involvement in SLE.
Optic nerve Choroid Retina
Prevalence 1% b1% 3% to 29%
Presentation Optic neuritis, ischemic
optic neuropathy
Serous retinal detachment, retinal pigment epithelium detachment, retinal
pigment epitheliopathy, choroidal ischemia, choroidal effusion
Microangiopathy, retinal vasculitis
and severe vaso-occlusion




Association to CNS lupus No Yes Yes
References Frigui et al. [51]
Man et al. [52]
Nguyen et al. [53]
Baglio et al. [54]
Stafford-Brady et al. [55]
Jabs et al. [56]
620 A. Dias-Santos et al. / Autoimmunity Reviews 17 (2018) 617–624nerve ﬁber layer, ganglion cell layer and ganglion cell complex (GCC),
comprising the ganglion cell layer and inner plexiform layer. Neuronal
retinal loss can actually be detected even in patients without afferent vi-
sual defects.
The rational for retinal thinning in SLE involves both direct retinal
damage and trans-synaptic retrograde degeneration (TRD). IgG im-
mune complexes in thewalls of retinal vessels are reportedly associated
to RNFL microinfarcts and ganglion cell atrophy [71]. Anti-NMDA anti-
bodies directed against NMDA receptors present on the surface of gan-
glion cells may also be pathogenic [72]. Moreover, TRD of neurons is a
process occurring after central nervous system lesions, in which degen-
eration of the axon proceeds towards the cell body, as opposed to anter-
ograde (Wallerian) degeneration. This results in a neurotoxic
microenvironment that leads to secondary degeneration of adjacent
neurons [73]. Optic disc pallor and band atrophy in individuals with
congenital occipital lesions have been described [74] and TRD of retinal
ganglion cells has been further described in acquired occipital lobe le-
sions [75–77]. Overall, both inﬂammation and neurodegeneration of
the posterior visual pathway may be accompanied by early retinal
changes.
2.4. The retrochiasmal visual pathway
Eye movement disorders are common in SLE. They have been re-
ported in up to 29% patients, often as a result of brainstem infarction
[78]. Visual cortex involvement can cause visual hallucinations, visual
ﬁeld defects, nystagmus, and cortical blindness [63]. Idiopathic intracra-
nial hypertension has also been reported both in children and adults
and may rarely be the presenting manifestation of SLE [79,80].
3. Imaging the retina, optic nerve and choroid in SLE
3.1. Fundus ﬂuorescein angiography and indocyanine angiography
Fundus ﬂuorescein angiography (FFA) is an invasive method that
may be helpful in identifying subclinical signs of retinopathy, manifest-
ing as leakage, retinal capillary dilatation and microaneurysms in pa-
tients with mild-to-moderate disease activity. It can also reveal optic
disc edema in cases of optic neuropathy. In severe vaso-occlusive reti-
nopathy, FFA may present major artery or vein occlusions or multiple
microembolisation in small vessels presenting as Purtscher-like reti-
nopathy [81,82]. The choroid can also be evaluated with FFA, which
may present delayed choroidal ﬁlling or areas of choroidal
nonperfusion. In more severe choroidopathy, FFAmay reveal multifocal
areas of subretinal leakage with pooling, corresponding to the areas of
exudative retinal detachment [53]. However, indocyanine green angi-
ography (IGA) is a more valuable exam to evaluate choroidal pathology.
Typically, it presents with focal, transient early-phase hypoﬂuorescence
secondary to perfusion delay followed by late-phase diffuse
hyperﬂuorescence due to vascular hyperpermeability. More subtleﬁnd-
ings include distortion of the large choroidal vessels and also pinpointclusters of choroidal hyperﬂuorescence in the intermediate phase that
may represent immune deposition in deeper layers of choroidal stroma
or Bruch membrane [83].
3.2. Spectral domain optical coherence tomography
Spectral domain optical coherence tomography (SD-OCT) is a re-
liable, non-invasive, trans-pupillary technique that provides high-
resolution cross-sectional images of the retina and the optic nerve
head, using a principle analogous to B-scan ultrasound. A beam of in-
frared light strikes the retina and the delayed light reﬂected from the
various layers of the retina and choroid is compared to a reference
beam projected against a mirror. The elaboration of the three-di-
mensional image is made based on the principles of low-coherence
interferometry. This method provides detailed data on the morphol-
ogy and reproducibly measures the thickness and volume of optic
nerve, peripapillary area and the various retinal layers at themacular
level (Figs. 1 and 2).
Classical OCT devices like time-domain OCT were unhelpful in
choroidal imaging, as the retinal pigment epithelium blocked the
signal from the choroid. New software for SD-OCT – enhanced
depth imaging (EDI) – maximizes sensitivity and detail by moving
the peak of the sensitivity curve to the sclera (Fig. 3). Thus it provides
a better view of the choroidal cross-sectional structure, thickness
and choroidal-scleral interface [84]. However, the few studies on
choroidal thickness in SLE patients revealed contradictory results.
According to Altinkaynak et al. SLE patients had thinner choroids
than age and gender-matched controls [85]. On the other hand,
Ferreira et al. reported thicker choroids in these patients [86]. This
difference may be due to the systemic disease activity state as in
the ﬁrst study all patients were “inactive” whereas in the latter
study the disease activity state was not accessed. An increase in cho-
roidal thickness with systemic inﬂammatory activity has also been
described in Behçet disease [87,88].
More recently, a new OCT system – optical coherence tomography
angiography (OCTA) – has the ability to show both structural and
blood ﬂow information without requiring intravenous contrast. This in-
novative technology, called split-spectrum amplitude decorrelation an-
giography, is based on the comparison of multiple B scans acquired
consecutively in the same spot. In the case of stationary tissues or
cells, there is a high correlation between consecutive images. For mov-
ing cells, such as blood cells inside the vessels, there is a low correlation
(or high decorrelation) between consecutive images, thereby revealing
the microvascular architecture [89].
Studies regarding retinal thicknessmeasurements have yielded con-
tradictory results (Table 3) likely explained on the basis of small sample
size and heterogeneity of clinical NPSLE manifestations and SLE sys-
temic disease activity [90,91].
Longitudinal studies as well as studies with larger samples are
needed to evaluate the real potential of OCT to detect early neurodegen-
erative changes and to eliminate the effect of potential confounders
Fig. 1. Peripapillary retinal nerve ﬁber layer. Peripapillary retinal nerve ﬁber layer thickness measurement with spectral domain optical coherence tomography (Spectralis Heidelberg®)
and comparison to a sex and age-matched database. ILM – internal limiting membrane; RNFL – retinal nerve ﬁber layer.
621A. Dias-Santos et al. / Autoimmunity Reviews 17 (2018) 617–624such as the effect of ocular axial length, intraocular pressure, ophthalmic
pathologies, systemic medications like hydroxychloroquine and other
systemic comorbidities, like diabetesmellitus, that potentially affect ret-
inal thickness [92]. Standardised questionnaires may also offer valuable
help for screening practices.Fig. 2.Macular segmentation.Macular scan obtainedwith spectral domain optical coherence to
ELM – external limiting membrane; GCL – ganglion cell layer; ILM – internal limiting membran
outer plexiform layer; PR1 – photoreceptors inner segments; PR2 – photoreceptors outer segm4. Conclusion
The retina is an extension of the central nervous system; retinal gan-
glion cells and their axons forming the optic nerve are similar to CNS
neurons and the retinal and cerebral vasculature share anatomic,mography, showing the segmentation of the various retinal layers. BM – Bruchmembrane;
e; INL – inner nuclear layer; IPL – inner plexiform layer; ONL – outer nuclear layer; OPL –
ents; RPE – retinal pigment epithelium.
Table 3
Published studies comparing retinal thickness and volume between NPSLE, non-NPSLE and healthy controls.














Liu et al. NPSLE patients
versus non-NPSLE [90]
15 NPSLE vs 16
non-NPSLE
No difference No difference No
difference
No difference No difference No difference
Liu et al. NPSLE patients
versus healthy controls [90]














SLE versus healthy controls
[90]




















absolute values in NPSLE
N.A. N.A. N.A. N.A. N.A.
a Macular inner retinal complex: between the internal limiting membrane and the inner edge of the inner nuclear layer.
b Ganglion cell complex: between the outer edge of the RNFL and the inner edge of the inner nuclear layer.
Fig. 3. Choroid. Choroidal thickness, measured using enhanced depth imaging (EDI) software for spectral domain optical coherence tomography (Spectralis Heidelberg®).
622 A. Dias-Santos et al. / Autoimmunity Reviews 17 (2018) 617–624physiological, and embryological similarities. Therefore, in some way
the retina can be considered a “window to the brain”. The utility of
OCT in tracking early signs of neurodegeneration has been demon-
strated in other pathologies. The idea of monitoring the neurodegener-
ative process associated with SLE would undoubtedly be an appealing
one. It would enable a better control of CNS involvement since the
early stages and open the way to studies in neuroprotection. However,
so far, the studies conducted in SLE have given inconsistent results. Ro-
bust studies are further needed to access the real potential of ophthal-
mic imaging in studying neurodegenerative changes associated with
SLE with respect to disease activity and cognition.
NPSLE is a frequent and severe complication of SLE,with a signiﬁcant
impact in quality of life and life expectancy. However, its diagnosis is an
ongoing challenge given themultitude of clinical syndromes and the ab-
sence of reliable diagnostic tools. Imagiologic signs of brain inﬂamma-
tion or atrophy are a frequent ﬁnding, not only in NPSLE but also in
SLE patients without neuropsychiatric manifestations. This suggests
that neurodegeneration in LES is a relentless continuous process,
starting long before the appearance of clinical signs of CNS involvement.
On the other hand, one can discuss the importance of this relent-
less neurodegenerative process in the algorithms of NPSLE: is it a
pathophysiologic process behind several NP syndromes like move-
ment disorders, anxiety, mood disorder, psychosis or cognitive dis-
function? Or should we consider lupic neurodegeneration the 20th
NP syndrome?
Take-home messages
• NPSLE is associated with a signiﬁcant impact in morbidity and life ex-
pectancy.• Early diagnosis of NPSLE is difﬁcult as there are no widely accepted
biomarkers.
• CNS inﬂammation and atrophy is present in lupus patients without
NPSLE.
• Retinal thinning on SD-OCT is an established biomarker of neurode-
generation.
• Experimental models suggest that neuroprotection may be feasible
and beneﬁcial in systemic inﬂammation.
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